Multi-biomarker pattern for tumor identification and prognosis

Journal of Cellular Biochemistry

Volumn 112, Issue 10, 2011, Pages 2703-2715

  Rodríguez Enríquez, Sara ^a,b   Pacheco Velázquez, Silvia Cecilia ^a   Gallardo Pérez, Juan Carlos ^a   Marín Hernández, Alvaro ^a   Aguilar Ponce, José Luis ^b   Ruiz García, Erika ^b   Ruizgodoy Rivera, Luz María ^b   Meneses García, Abelardo ^b   Moreno Sánchez, Rafael ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

biomarker patterns; glycolytic genes; HIF 1 ; metabolic biomarkers

Indexed keywords

BIOLOGICAL MARKER; BROXURIDINE; CA 125 ANTIGEN; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLIN D1; CYCLIN E; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; K RAS PROTEIN; KI 67 ANTIGEN; MITOMYCIN C; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P27; PROTEIN P53; TAMOXIFEN; THYMIDINE; UNINDEXED DRUG; VASCULOTROPIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME 18Q; COLORECTAL CANCER; FLOW CYTOMETRY; GENE MUTATION; GLIOMA; HETEROZYGOSITY LOSS; HYPOXIA; MASTECTOMY; METABOLIC REGULATION; MICROSATELLITE INSTABILITY; MYELOID LEUKEMIA; OVARY CANCER; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL; UTERINE CERVIX CANCER;

HUMANS; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 80053184390     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23224     Document Type: Article

References (139)

1. Abourbih DA, Di Cesare S, Orellana ME, Antecka E, Martins C, Petruccelli LA, Burnier MN, Jr., 2010. Lysyl oxidase expression and inhibition in uveal melanoma. Melanoma Res 20: 97-106.
2. Alberghina L, Westerhoff HV,. 2005. Systems biology: Definitions and perspectives. First edition. Berlin: Springer.
3. Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, Rehrauer H, Tinguely M, Moch H, Hegyi I,. 2010. Lysyl oxidase expression is an independent marker of prognosis and predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer 126: 2653-2662.
4. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tria Tirona M, Goldberg RM,. 2002. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20: 1735-1743. (Pubitemid 34273261)
5. Allred DC, Brown P, Medina D,. 2004. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 6: 240-245. (Pubitemid 39440252)
6. Alsheyab F, Abbas M, Mosameh Y, Ali S,. 2009. Immunohistochemical prognostic indicators of lymphoma tumors. Afr J Biotechnol 8: 5025-5029.
7. Altenberg B, Greulich KO,. 2004. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020. (Pubitemid 39469126)
8. Arens N, Bleyl U, Hildenbrand R,. 2005. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 446: 489-496. (Pubitemid 40884281)
9. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, Bucala R,. 2002. High expression of inducible 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62: 5881-5887. (Pubitemid 35204749)
10. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ,. 2007. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 8: 1705-1713.
11. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
12. Beresford MJ, Wilson GD, Makris A,. 2006. Measuring proliferation in breast cancer: Practicalities and applications. Breast Cancer Res 8: 216.
13. Berny W, Weiser A, Markowska-Woyciechowska A, Jarmundowicz W, Zub W, Załuski R,. 2004. Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors. Neurol Neurochir Pol 38: 457-463.
14. Boren J, Montoya AR, de Atauri P, Comin-Anduix B, Cortes A, Centelles JJ, Frederiks WM, Van Noorden CJ, Cascante M,. 2002. Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: A new strategy for antitumor drug development. Mol Biol Rep 29: 7-12. (Pubitemid 35021850)
15. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF,. 2002. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20: 379-387. (Pubitemid 34072519)
16. Buyse M,. 2007. Towards the validation of statistically reliable biomarkers. Eur J Cancer 41: 89-95. (Pubitemid 350017011)
17. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A,. 2010. Biomarkers and surrogate end points-The challenge of statistical validation. Nat Rev Clin Oncol 7: 309-317.
18. Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, Yang AS,. 2007. Examination of IGF2 and H19 loss imprinting in bladder cancer. Cancer Res 67: 10753-10758. (Pubitemid 350145902)
19. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S, Scambia G,. 2001. GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer 92: 1144-1150. (Pubitemid 32861663)
20. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J,. 1992. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 68: 357-363. (Pubitemid 23013251)
21. Chang YS, Wu W, Walsh G, Hong WK, Mao L,. 2003. Enolase-a is frequently down regulated in non small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 9: 3641-3644. (Pubitemid 37169229)
22. Chaudhry P, Srinivasan R, Patel FD,. 2010. Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome. Oncol Res 18: 549-559.
23. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P,. 1996. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 2: 1033-1035. (Pubitemid 26306844)
24. Chow NH, Tzai TS, Cheng HL, Liu HS, Chan SH, Tong YC,. 2000. The clinical value of p21WAF1/CIP1 expression in superficial bladder cancer. Anticancer Res 20: 1173-1176.
25. Cianga C, Cianga P, Cozma L, Diaconu C, Carasevici E,. 2002. Low p27(Kip1)expression is associated with poor prognostic factors in breast carcinomas. J BUON 7: 117-120. (Pubitemid 34812033)
26. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccardt MJ,. 2005. Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 16: 1723-1739. (Pubitemid 41631235)
27. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, Powe NR, Feinberg AP,. 2003. Loss of IGF2 Imprinting: A Potential marker of colorectal cancer risk. Science 299: 1753-1755. (Pubitemid 36337205)
28. Dales JP, Beaufils N, Silvy M, Picard C, Pauly V, Pradel V, Formisano-Tréziny C, Bonnier P, Giusiano S, Charpin C, Gabert J,. 2010. Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: Potential prognostic biomarkers in breast cancer. BMC Med 8: 44.
29. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB,. 2007. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104: 19345-19350.
30. DeBerardinis RJ, Lum JL, Hatzivassiliou G, Thompson CB,. 2008. The Biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
31. Ding H, Roncari L, Wu X, Lau N, Shannon P, Nagy A, Guha A,. 2001. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro-oncol 3: 1-10. (Pubitemid 33685580)
32. Douglas-Jones AG, Collet N, Morgan JM, Jasani B,. 2001. Comparison of core oestrogen receptor (ER) assay with excised tumour: Intratumoral distribution of ER in breast carcinoma. J Clin Pathol 54: 951-955. (Pubitemid 34032891)
33. Durany N, Joseph J, Cruz-Sánchez FF, Carreras J,. 1997. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and creatine kinase activity and isoenzymes in human brain tumours. Br J Cancer 76: 1139-1149. (Pubitemid 27448009)
34. Fan Y, Wang J, Yang Y, Liu Q, Fan Y, Yu J, Zheng S, Li M, Wang J,. 2010. Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol 136: 1243-1254.
35. Faratian D, Clyde RG, Crawford JW, Harrison DJ,. 2009. Systems pathology-taking molecular pathology into a new dimension. Nat Rev Clin Oncol 6: 455-464.
36. Fell D,. 1997. Understanding the control of metabolism. London: Portland Press. p 301.
37. Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, Testa AC, Werner U, Navarra P, Tringali G, Battaglia A, Scambia G,. 2003. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: A pilot study. Clin Cancer Res 9: 4324-4331. (Pubitemid 37248387)
38. Gangadhar T, Schilsky RL,. 2010. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol 7: 318-325.
39. Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JR, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F,. 1992. Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10: 686-695.
40. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB,. 2006. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12: 4562-4568. (Pubitemid 44297805)
41. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P,. 2008. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100: 14-20. (Pubitemid 351767337)
42. Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, Koukourakis MI,. 2006. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol 103: 912-918. (Pubitemid 44821314)
43. Glas AS, Hollema H, Nap RE, Plukker JT,. 2002. Expression of estrogen, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer 94: 2211-2216. (Pubitemid 34411979)
44. Goede V, Coutelle O, Neuneler J, Reinacher-Schick A, Schnell R, Koslowsky TC, Welhrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT,. 2010. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103: 1407-1414.
45. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ,. 2006. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol 19: 1429-1436. (Pubitemid 44624161)
46. Groen AK, Westerhoff HV,. 1990. Modern control theories. A consumer's test. In:, Cornish-Bowden A, Cardenas ML, editors. In control of metabolic process. New York: Plenum Press. pp 101-118.
47. Guo-Qing P, Yuan Y, Cai-Gao Z, Hongling Y, Gonghua H, Yan T,. 2010. A study of association between expression of hOGG1, VDAC1, HK-2 and cervical carcinoma. J Exp Clin Cancer Res 29: 129.
48. Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan ML, Antonescu CR,. 2010. IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol 221: 300-307.
49. Hayes DF,. 2005. Prognostic and predictive factors revisited. Breast 14: 493-499. (Pubitemid 41683571)
50. Höckel M, Vaupel P,. 2001. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276. (Pubitemid 32219813)
51. Hodgkiss RJ,. 1998. Use of 2-nitromidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 13: 687-702. (Pubitemid 28410155)
52. Hofmeyr JS, Cornish-Bowden A,. 2000. Regulating the cellular economy of supply and demand. FEBS Lett 476: 47-51. (Pubitemid 30394648)
53. Horan AD, Koch CJ,. 2001. The K(m) for radiosensitization of human tumor cells by oxygen is much greater than 3mmHg and is further increased by elevated levels of cysteine. Radiat Res 156: 388-398. (Pubitemid 32904992)
54. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB,. 2010. Insuline-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 16: 2999-3010.
55. Inoue T, Uchino S, Shiraishi N, Adachi Y, Kitano S,. 1998. Loss of heterozygosity on chromosome 18q in cohesive-type gastric cancer is associated with tumor progression and poor prognosis. Clin Cancer Res 4: 973-977. (Pubitemid 28183399)
56. Isidoro A, Martínez M, Fernández PL, Ortega AD, Santamaría G, Chamorro M, Reed JC, Cuezva JM,. 2004. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oedophageal cancer. Biochem J 378: 17-20. (Pubitemid 38299539)
57. Johann DJ, Jr, Wei BR, Prieto DA, Chan KC, Ye X, Valera VA, Simpson RM, Rudnick PA, Xiao Z, Issaq HJ, Linehan WM, Stein SE, Veenstra TD, Blonder J,. 2010. Combined blood/tissue analysis for cancer biomarker discovery: Application to renal cell carcinoma. Anal Chem 82: 1584-1588.
58. Kacser H, Burns JA,. 1973. The control of flux. Symp Soc Exp Biol 27: 65-104.
59. Karam AK, Karlan BY,. 2010. Ovarian cancer: The duplicity of ca125 measurement. Nat Rev Clin Oncol 7: 335-339.
60. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR,. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
61. Kemik O, Sumer A, Sarbay-Kemik A, Purisa S, Tuzun S,. 2010. Circulating levels of VEGF family and their receptors in hepatocellular carcinoma. Bratisl Lek Listy 111: 485-488.
62. Kim HT, Choi BH, Niikawa N, Lee TS, Chang SI,. 1998. Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. Am J Med Genet 80: 391-395. (Pubitemid 28541605)
63. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondón G, Champlin RE, Sahin AA, Ueno NT,. 2001. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7: 4008-4012. (Pubitemid 34044620)
64. Knowles HJ, Harris AL,. 2001. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res 3: 318-322.
65. Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S,. 2010. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: Effects of preoperative chemotherapy. BMC Cancer 10: 320.
66. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL,. 2003. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89: 877-885. (Pubitemid 37175811)
67. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL,. 2006. Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway-A report of the Tumour Angiogenesis Research Group. J Clin Oncol 24: 4301-4308. (Pubitemid 46630788)
68. Krebs HA,. 1970. Rate control of the tricarboxylic acid cycle. Adv Enzyme Regul 8: 335-353.
69. Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, Rudolph P,. 2003. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 199: 424-431. (Pubitemid 36411218)
70. Lehar J, Krueger A, Zimmermann G, Borisy A,. 2008. High-order combination effects and biological robustness. Mol Syst Biol 4: 215.
71. Lesko LJ, Atkinson AJ, Jr., 2001. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41: 347-366. (Pubitemid 32390116)
72. Levkoff LH, Marshall GP II, Ross HH, Caldeira M, Reynolds BA, Cakiroglu M, Mariani CL, Streit WJ, Laywell ED,. 2008. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia 10: 804-816.
73. Li HX, Lei DS, Wang XQ, Skog S, He Q,. 2005. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep 13: 145-149.
74. Marín-Hernández A, Rodríguez-Enríquez S, Vital-González PA, Flores-Rodríguez FL, Macías-Silva M, Sosa-Garrocho M, Moreno-Sánchez R,. 2006. Determining and understanding the control of glycolysis in fast-growth tumor cells. 2006. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 273: 1975-1988.
75. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S, Moreno-Sánchez R,. 2009. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9: 1084-1101.
76. Marín-Hernández A, Gallardo-Pérez JC, Rodríguez-Enríquez S, Encalada R, Moreno-Sánchez R, Saavedra E,. 2010. Modeling cancer glycolysis. Biochim Biophys Acta 1807: 755-767.
77. Markowitz SD, Bertagnolli MM,. 2009. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460.
78. Mayeux R,. 2004. Biomarkers: Potential uses and limitations. NeuroRx 1: 182-188. (Pubitemid 46589350)
79. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE,. 2007. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
80. Moreno-Sánchez R, Saavedra E, Rodríguez-Enríquez S, Olín-Sandoval V,. 2008. Metabolic control analysis: A tool for designing strategies to manipúlate metabolic pathways. J Biomed Biotechnol 2008: 597913.
81. Moreno-Sánchez R, Saavedra E, Rodríguez-Enríquez S, Gallardo-Pérez JC, Quezada H, Westerhoff HV,. 2010. Metabolic control analysis indicates a change of strategy in the treatment of cancer. Mitochondrion 10: 626-639.
82. Morero JL, Poleri C, Martín C, Van Kooten M, Chacón R, Rosenberg M,. 2007. Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients. J Thorac Oncol 2: 293-298. (Pubitemid 47181711)
83. Nagy JA, Chang SH, Dvorak AM, Dvorak HF,. 2009. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100: 865-869.
84. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D,. 1996. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2: 1035-1037. (Pubitemid 26306845)
85. Newsholme EA, Start CS,. 1973. Regulation of metabolism. London: John Wiley and Sons. p 349.
86. Ng IO, Lai EC, Fan ST, Ng M, Chan AS, So MK,. 1994. Pronostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 73: 2268-2274. (Pubitemid 24129107)
87. Nowicki M, Ostalska-Nowicka D, Miśkowiak B,. 2006. Prognostic significance of Ki67-negative blast cell clone in the high risk group of children treated for acute myeloid leukaemia. Folia Histochem Cytobiol 44: 49-52. (Pubitemid 43224827)
88. Nunez R,. 2001. DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol 3: 67-70. (Pubitemid 32677840)
89. Padilla D, Cubo T, Villarejo P, López A, García M, de la Plaza R, Jara A, Menéndez P, Gambí D, Menchén B, Pardo R, Martín J,. 2007. Molecular profile of node-negative colorectal cancer of poor prognosis using immunohistochemical determination of p53, ki67, VEGF, and metalloproteinase-9. Rev Esp Enferm Dig 99: 424-425.
90. Papantoniou VJ, Souvatzoglou MA, Volatassiou VJ, Louvrou AN, Ambela C, Koutsikos J, Lazaris D, Christodoulidou JK, Sotiropoulou MG, Melissinou MJ, Perperoglou A, Zerva CJ,. 2004. Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer. Breast Cancer Res 6: R56-R62.
91. Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, Catton C, Catton P, Crook J, Gospodarowicz M, McLean M, Warde P, Hill RP,. 2004. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 58: 750-757. (Pubitemid 38221131)
92. Pegram MD, Pauletti G, Slamon DJ,. 1998. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52: 65-77. (Pubitemid 29056086)
93. Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelénat H,. 1996. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37: 57-64. (Pubitemid 26028246)
94. Pinto AE, Silva G, Banito A, Leite V, Soares J,. 2008. Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma. Oncol Rep 20: 913-919.
95. Quasar Collaborative Group. 2007. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370: 2020-2029.
96. Reichert JM,. 2011. Antibody-based therapeutics to watch in 2011. MAbs 3: 76-99.
97. Riley RD, Sauerbrei W, Altman DG,. 2009. Prognostic markers in cancer: The evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100: 1219-1229.
98. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA,. 2010. Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28: 4769-4777.
99. Rodríguez-Enríquez S, Torres-Márquez ME, Moreno-Sánchez R,. 2000. Substrate oxidation and ATP supply in AS-30D hepatoma cells. Arch Biochem Biophys 375: 21-30. (Pubitemid 30133617)
100. Rodríguez-Enríquez S, Carreño-Fuentes L, Gallardo-Pérez JC, Saavedra E, Quezada H, Vega A, Marín- Hernández A, Olín-Sandoval V, Torres-Márquez ME, Moreno-Sánchez R,. 2010. Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma. Int J Biochem Cell Biol 42: 1744-1751.
101. Rolleston FS,. 1972. A theoretical background to the use of measured concentrations of intermediates in study of the control of intermediary metabolism. Curr Top Cell Regul 5: 47-75.
102. Sakata K, Someya M, Nagakura H, Nakata K, Oouchi A, Hareyama M, Satoh M,. 2006. A clinical study of hypoxia using endogenous hypoxic markers and polarographic oxygen electrodes. Strahlenther Onkol 182: 511-517. (Pubitemid 44316239)
103. Savage P, Stebbing J, Bower M, Crook T,. 2009. Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol 6: 43-52.
104. Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S,. 2010. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 12: 361-371.
105. Seo HK, Cho KS, Chung J, Joung JY, Park WS, Chung MK, Lee KH,. 2010. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy. Urology 76: 1-7.
106. Settarkorn J, Kaewpila N, Burns GF, Leong AS,. 2005. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol 58: 1249-1254. (Pubitemid 41752767)
107. Shoshan MC, Linder S,. 2008. Target specificity and off-target effects as determinants of cancer drug efficacy. Expert Opin Drug Metab Toxicol 4: 273-280. (Pubitemid 351618773)
108. Siah SP, Quinn DM, Bennet GD, Casey G, Flower RLP, Suthers G, Rudzki Z,. 2000. Microsatellite instability markers in breast cancer: A review and study showing MSI was not detected at BAT25 and BAT26 microsatellite markers in early-onset breast cancer. Breast Cancer Res Treat 60: 135-142. (Pubitemid 30307473)
109. Smolková K, Bellance N, Sacndurra F, Génot E, Gnaiger E, Plecitá-Hlavatá L, Jezek P, Rossignol R,. 2010. Mitochondrial bionenergetic adaptations of breast cáncer cells to aglycemia and hipoxia. J Bioenerg Biomembr 42: 55-67.
110. Snoep JL,. 2005. The silicon cell initiative: Working towards a detailed kinetic description at the cellular level. Curr Opin Biotechnol 16: 336-343. (Pubitemid 40806472)
111. Soukup V, Babjuk M, Dusková J, Pesl M, Szakácsova M, Zamefnik L, Dvorácek J,. 2007. The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer. Cas Lek Cesk 146: 63-67. (Pubitemid 46113002)
112. Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V,. 2002. Correlation between MIB-1 andother proliferation markers: Clinical implications of the MIB-1cutoff value. Cancer 94: 2151-2159. (Pubitemid 34411971)
113. Stackievicz R, Paran H, Bernheim J, Shapira M, Weisenberg N, Kaufman T, Klein E, Gutman M,. 2010. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J 12: 290-295.
114. Subramanian J, Simon R,. 2010. What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol 7: 327-334.
115. Sullivan RP, Mortimer G, Muircheartaigh IO,. 1993. Cell proliferation in breast tumours: Analysis of histological parameters Ki67 and PCNA expression. Ir J Med Sci 162: 343-347. (Pubitemid 23310941)
116. Sun R, Eriksson S, Wang L,. 2010. Identification and characterization of mitochondrial factors modulating thymidine kinase 2 activity. Nucleosides Nucleotides Nucleic Acids 29: 382-385.
117. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M,. 2006. Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol 21: 713-720. (Pubitemid 44082713)
118. Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K,. 2010. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu. Prostate 70: 1395-1401.
119. ter Kuile BH, Westerhoff HV,. 2001. Transcriptome meets metabolome: Hierarchical and metabolic regulation of the glycolytic pathway. FEBS Lett 500: 169-171. (Pubitemid 32607554)
120. Tesan T, Gustavsson H, Welen K, Damber JE,. 2008. Differential expression of angiopoietin-2 and vascular growth factor in androgen-independent prostate cancer models. BJU Int 102: 1034-1039.
121. Timár J, Rásó E, Honk KV, Hangmann W,. 1999. 12-Lipoxygenase expression in human melanoma cell lines. Adv Exp Med Biol 469: 617-622.
122. Toffoli S, Michielis C,. 2008. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 275: 2991-3002. (Pubitemid 351743577)
123. van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA,. 2010. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based study. Gynecol Oncol 119: 265-269.
124. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R,. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009. (Pubitemid 35461656)
125. Van Roozendaal CE, Gillis AJ, Klijn JG, Ooijen B, Claasen CJ, Eggermont AM, Henzen-Logmans SC, Oosterhuis JW, Foekens JA, Looijenga LH,. 1998. Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett 437: 107-111. (Pubitemid 28498250)
126. Vassilopoulos I, Korkolopoulou P, Konstantinidou AE, Patsouris E, Eftichiadis C, Thymara I, Perdiki M, Pavlakis K, Agapitos E, Davaris PS,. 2003. Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas. Histol Histopathol 18: 761-770. (Pubitemid 36773221)
127. Vizán P, Alcarraz-Vizán G, Díaz-Moralli S, Solovjeva ON, Frederiks WM, Cascante M,. 2009. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 24: 2789-2796.
128. Vu TH, Nguyen AH, Hoffman AR,. 2010. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Hum Mol Genet 19: 901-919.
129. Webster L, Hodgkiss RJ, Wilson GD,. 1998. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br J Cancer 77: 227-234. (Pubitemid 28029539)
130. Weidemann A, Johnson RS,. 2008. Biology of HIF-1alpha. Cell Death Differ 15: 621-627.
131. Westerhoff HV, Winder C, Messiha H, Simeonidis E, Adamczyk M, Verma M, Bruggeman FJ, Dunn W,. 2009. Systems biology: The elements and principles of life. FEBS Lett 583: 3882-3890.
132. Westerhoff HV, Kolodkin A, Conradie R,., et al. 2009b. Systems biology towards life in silico: Mathematics of the control of living cells. J Math Biol 58: 7-34.
133. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY,. 2005. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23: 8136-8139. (Pubitemid 46657433)
134. Wootipoom V, Lekhyananda N, Phungrassami T, Boonyaphiphat P, Thongsuksai P,. 2004. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol 94: 636-642. (Pubitemid 39194454)
135. Yasuda S, Arii S, Mori A, Isobe N, Yang W, Oe H, Fujimoto A, Yonenaga Y, Sakashita H, Imamura M,. 2004. Hexokinase II and VEGF expression in liver tumors: Correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol 40: 117-123. (Pubitemid 38064720)
136. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT,. 1997a. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80: 1046-1051. (Pubitemid 27427603)
137. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J,. 1997b. Immunohistochemical detection of Glut3 in human tumors and normal tissues. Anticancer Res 17: 2747-2750. (Pubitemid 27352681)
138. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW,. 1999. Overexpression of hipoxia-inducible factors 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835.
139. Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, Mori Y, Shibata D, Sato F, Wang S, Olaru A, Deacu E, Liu TC, Abraham JM, Meltzer SJ,. 2002. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing